Enanta Pharmaceuticals Stock News

ENTA earnings call for the period ending December 31, 2021.

ENTA earnings call for the period ending December 31, 2021.

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q1 2022 Results - Earnings Call Transcript

Enanta Pharma press release (ENTA): Q1 GAAP EPS of -$1.48 misses by $0.37.Revenue of $27.65M (-12.9% Y/Y) beats by $0.28M.

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -30.97% and 3.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -30.97% and 3.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

Enanta Pharma (NASDAQ:ENTA) is scheduled to announce Q1 earnings results on Tuesday, February 8th, after market close.The consensus EPS Estimate is -$1.11 and the consensus Revenue

Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Tarrytown, New York, Jan. 24, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) is pleased to announce that the practice has formed a clinical affiliation with Cooperman Barnabas Medical Center (CBMC), formerly Saint Barnabas Medical Center. "We are thrilled to affiliate and collaborate with ENT and Allergy Associates. ENTA is recognized throughout the region as a leader providing outstanding care to their patients," states Richard L. Davis, President and CEO, Cooperman Barnabas Medical Center. This affiliation offers New Jersey residents access to enhanced otolaryngology and allergy healthcare services across a wide variety of specialties and sub-specialties, provided by CBMC. ENTA plans to integrate its NextGen Electronic Health Records system with CBMC to create a single button protocol that will help quickly and efficiently coordinate care between physicians and facilities. Patients who are found to need tertiary care will be quickly seen by the specialist within 48 hours.

The shares of Enanta Pharmaceuticals <> dropped for the third straight session to reach over a three-month low after SVB Leerink cut its price target, highlighting the concerns on

Enanta Pharmaceuticals <> provided updates on its pipeline and said President and CEO Jay Luly will shed light on the virology programs and plans for 2022 at the 40th Annual J.P

Mallinckrodt (OTCMKTS:MNKKQ) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation. Analyst Ratings This is a summary of recent recommendations for Mallinckrodt and Enanta Pharmaceuticals, as reported []

Equities research analysts expect Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to announce sales of $25.86 million for the current quarter, according to Zacks. Three analysts have provided estimates for Enanta Pharmaceuticals earnings. The highest sales estimate is $30.26 million and the lowest is $19.61 million. Enanta Pharmaceuticals posted sales of $31.74 million in the same quarter last []

Analysts expect Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to post earnings of ($1.27) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Enanta Pharmaceuticals earnings. The highest EPS estimate is ($1.18) and the lowest is ($1.43). Enanta Pharmaceuticals posted earnings of ($0.41) per share during the same quarter []